RLS Global presents data about ChloraSolv and its rapid response and high efficacy on biofilm
At the EWMA (European Wound Management Association) Conference in November, RLS will present data where our technology has been evaluated in an ex-vivo wound model with very exciting results on biofilm. The evaluation was carried out together with RISE, Research Institute of Sweden.
Biofilm is challenging in Wound Management. Staphylococcus aureus and Pseudomonas aeruginosa are two common bacteria that form biofilms in chronic wounds. A biofilm is formed by a high number of bacteria that protect themselves through a secretion of a viscous barrier. One consequence of biofilm formation is that the individual’s ability to kill bacteria through their immune system is hindered. Another consequence is that the bacteria is protected from antibiotics and several antiseptics.
The purpose of the study was to investigate the effect of ChloraSolv on these two bacteria. The results show that ChloraSolv has a rapid effect on both bacteria. In Staphylococcus aureus biofilm, 33% of the bacteria were killed in 30 seconds and more than 81% in five minutes. The effect on Pseudomonas aeruginosa is more immediate and kills more than 95% after 30 seconds. After five minutes, 97% of the bacteria are gone from the wound model.
To follow up on these results, RLS initiated a research program together with scientists from Lund University. The purpose is to investigate ChloraSolv’s effect on new biofilm models. The aim was to investigate biofilm reduction in the treatment of chronic wounds, but also in new clinical areas such as dermatology and burns. The results so far are very promising and will be published in a scientific journal.
‘RLS’s long-term strategy is to broaden the company’s product portfolio with products in new clinical areas. It is gratifying that we have now produced new, promising data that support our product development strategy, says Karin Fischer, CEO RLS Global. Karin continues, RLS has a unique platform with its buffered hypochlorite solution that has great potential for areas where biofilm is a problem.’
Trading place and Certified Advisor
RLS Global’s shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.
CONTACT INFORMATION
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702 48 46 51
Mats Ahlenius, CTO
E-mail: mats.ahlenius@rlsglobal.se
Telephone: +46 707 41 03 39
ABOUT RLS GLOBAL
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North Growth Market. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se Read more at www.rls.global